Navigation Links
Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
Date:2/11/2008

- New Agreement Provides for Development and Promotion of OraQuick(R) HCV

Test Outside the United States -

KENILWORTH, N.J., and BETHLEHEM, Pa., Feb. 11 /PRNewswire/ -- Schering- Plough Corporation (NYSE: SGP) and OraSure Technologies, Inc. (Nasdaq: OSUR) today announced an agreement to collaborate on the development and promotion of a rapid oral hepatitis C virus (HCV) test utilizing OraSure Technologies' OraQuick(R) technology platform on a worldwide basis outside the United States.

This new agreement expands the existing collaboration announced in January 2007 when the parties signed an agreement to develop and promote a rapid oral HCV test in the U.S. physicians' office markets. OraSure is a leader in oral fluid diagnostics and developer and manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, the first and only U.S. Food and Drug Administration (FDA) approved rapid oral fluid HIV-1/2 Test. Schering-Plough is a worldwide leader in the discovery and development of novel HCV therapies.

"We are very pleased to announce the expansion of our collaboration with Schering-Plough internationally," said Douglas A. Michels, President and CEO of OraSure Technologies. "Schering-Plough is a recognized leader in HCV therapy and has the capability to promote our rapid HCV test throughout the world. We believe the global market opportunity for a rapid HCV test is significant and this expansion of our collaboration with Schering-Plough should help drive the adoption of this important product around the world."

Under terms of the agreement, Schering-Plough will reimburse OraSure for certain development costs and will provide payments to OraSure based on the achievement of certain regulatory
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
2. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
3. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
6. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
7. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
8. Schering-Plough Completes Acquisition of Organon BioSciences
9. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
10. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
11. Schering-Plough Announces Pricing of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Philadelphia, PA (PRWEB) June 18, 2013 ... fiber-optic Ball Lenses engineered of synthetic Sapphire and Glass ... stock sizes from Swiss Jewel Company , of ... performance by expanding and collimating the light beams without ... extreme optical clarity and natural durability (9 mohs) make ...
(Date:6/18/2013)... June 18, 2013 DuPont welcomes 48 ... 11th annual DuPont National AgriScience Teachers Ambassador Academy this ... in Chestertown, Md. , The NATAA “Ag ... and is a special project of the National ... Agricultural Educators (NAAE) . The highly recommended agriscience ...
(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
(Date:6/18/2013)... June 18, 2013  regulated information — Global biopharmaceutical ... today announced the launch of a new Pledge ... The Pledge empowers the millions ... and make a personal commitment to demand more: greater ... care team and additional partial-onset seizure control.  More information ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... Funding Milestone Continues Progress at Seneca, Illinois ... ... NBF ) announced today that it has satisfied the conditions ... million,senior secured credit facility with WestLB AG, one of the world,s ...
... Phase 2b Trial Expected to Begin in the ... 4 Mpex Pharmaceuticals, Inc. today,announced that the ... Products Development has granted Mpex orphan drug designation ... pulmonary,infections due to Pseudomonas aeruginosa and other bacteria ...
... the Chinese Pharmaceutical ... CHENGDU, China, March 4 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, ... and,supplier of modernized traditional Chinese medicine ("TCM") based ... members:,Professor Zunjian Zhang, Ph.D., Professor Jianping Hou, Ph.D. ...
Cached Biology Technology:Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 2Tianyin Pharmaceutical Appoints Three New Independent Board Members 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 4
(Date:6/19/2013)... 2013  New York College of Health Professions announces ... and Trademark Office for detecting biometric changes through smart ... have been injured, attacked or killed. This ... Intellectual Properties Agreements of New York College of Health ... New York College says, "Our ...
(Date:6/19/2013)... expected to contribute to a very large and potentially ... a University of Michigan ecologist and colleagues who released ... Chesapeake Bay. , The Gulf forecast, one of two ... for an oxygen-depleted, or hypoxic, region of between 7,286 ... the 10 largest on record. , The low end ...
(Date:6/19/2013)... June 19, 2013 Elsevier, a world-leading provider of ... pleased to announce the launch of a new open ... launch of GeoResJ , Elsevier,s earth and planetary ... journal. The journal aims to provide a forum for ... science field. The journal will be co-edited by six ...
Breaking Biology News(10 mins):New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... supported by the National Institute on Drug Abuse (NIDA), ... the first time identified genes that might increase a ... was conducted by Dr. George Uhl at NIDA’s Intramural ... Rose at the Center for Nicotine and Smoking Cessation ...
... Diseases (NIAID), part of the National Institutes of Health ... year for seven years to establish six Centers of ... will expand NIAID’s influenza surveillance program internationally and in ... key areas, including understanding how the virus causes disease ...
... reduced calorie intake can increase health and longevity. Professor ... discovered that reducing calorie intake later in life can ... of life-long calorie reduction. Importantly, this also includes anti-cancer ... establish a novel screening technique to find drugs which ...
Cached Biology News:NIDA study identifies genes that might help some people abstain from smoking 2NIAID expands capability for influenza research and surveillance 2NIAID expands capability for influenza research and surveillance 3NIAID expands capability for influenza research and surveillance 4It's never too late to get it back! Aging interrupted 2
in vitro Translation, Accessory Products...
Request Info...
... are K-12 derivatives that have mutations in ... reductase (gor) genes, which greatly enhances disulfide ... shown that expression in Origami(DE3) yielded 10-fold ... even though overall expression levels were similar ...
Request Info...
Biology Products: